ACIU · AC Immune SA

📣 What ACIU Says Is Next

• H1 2027 · “Supported by a strong preclinical data package (including 3-month toxicology data), ACI-19764 continues to advance through its Phase 1/1b clinical study, with additional data expected in H1 2027. ​ About ACI-19764 ACI-19764 is an orally available, brain penetrant, small molecule drug candidate which specifically inhibits the NLRP3 inflammasome.”
  Company press release, Aug 20, 2026 · SEC filing
• year end · “Recruitment of this Phase 1b cohort is ongoing and initial results are expected before year end.”
  Company press release, Aug 20, 2026 · SEC filing
• H1 2027 · “Full results from the Phase 1/1b trial are expected in H1 2027 ​ Lausanne, Switzerland, August 20 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases , today announced positive interim results from a Phase 1 first-in-human clinical study evaluating ACI-19764, its wholly-owned, orally administered small molecule inhibitor of the NLRP3 inflammasome.”
  Company press release, Aug 20, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Nov 2026 · Early Phase 1 · Recruiting · [18F]ACI-19626 PET in TDP-43 Proteinopathies
  Registry primary completion date, not a results date
• Dec 2026 · Phase 1 · Recruiting · A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune Sy
  Registry primary completion date, not a results date
• Jun 2028 · Phase 2 · Active Trial · A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson
  Registry primary completion date, not a results date
• Apr 2029 · Phase 1/2 · Recruiting · A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (A
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not ACIU's own candidates): ACI-24.060 with an additional adjuvant at Dose E in Study, ACI-24.060 with an additional adjuvant at Dose D in Study.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACIU holds $75.4M in cash and short-term investments and burns about $12.6M/quarter from operations, an estimated runway of 17.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

• Cash runway 18 months +18
• ATM program on file since Aug 2024 +15
• Shelf registration (F-3, Mar 2024) +10

Recent financing filings on SEC EDGAR:

• Aug 6, 2024 · ATM program, up to $80M · 424B5
• Mar 14, 2024 · Shelf registration, up to $350M · F-3
• Dec 15, 2023 · Underwritten offering, $50M · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACIU files for a raise →

👥 Who Owns ACIU

Share count 101,742,231 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.